A fluorescent labeled pyrazole derivative with a dansyl moiety () was synthesized. Design of was carried out by using a dansyl moiety to substitute the naphthalene moiety of the parent compound (). At a concentration of 30 µM, displayed biological activity on inducing a triple response in seedlings. Compared with the non-chemical treated control, the hypocotyl length of -treated seedlings was reduced from approximately 9.2±0.7 mm to 2.4±0.2 mm. The length of the roots was reduced from 1.7±0.1 mm to 1.0±0.1 mm, and the curvature of the hook of seedlings increased from 60±16 degrees to 245±35 degrees. The maxim excitation wavelength and emission wavelength of were 350 and 535 nm, respectively. Data obtained fluorescent microscope analysis indicated that intensive fluorescent signals of were observed in the shoot of seedlings.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9716048 | PMC |
| http://dx.doi.org/10.1584/jpestics.D22-006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Neoadjuvant darolutamide plus androgen deprivation therapy for high-risk and locally advanced prostate cancer: a multicenter, open-label, single-arm, phase II trial.
World J Urol
January 2025
Department of Urology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Propose: This study aimed to evaluate the efficacy and safety of neoadjuvant treatment of darolutamide, a next-generation androgen receptor inhibitor, plus androgen deprivation therapy (ADT) for patients with locally advanced prostate cancer (LAPC).
Methods: This single-arm, multicenter, open-label phase II trial (ClinicalTrials.gov: NCT05249712, 2022-01-01), recruited 30 localized high-risk/very high-risk prostate cancer (HRPCa/VHRPCa) patients from three centers in China between 2021 and 2023.
Development and Evaluation in Rat and Monkey of a Candidate Homochiral Radioligand for PET Studies of Brain Receptor Interacting Protein Kinase 1: [F]()-1-(5-(3-Fluorophenyl)-4,5-dihydro-1-pyrazol-1-yl)-2,2-dimethylpropan-1-one.
ACS Chem Neurosci
January 2025
Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, 10 Center Drive, Bethesda, Maryland 20892, United States.
Receptor interacting protein kinase 1 (RIPK1) crucially upregulates necroptosis and is a key driver of inflammation. An effective PET radioligand for imaging brain RIPK1 would be useful for further exploring the role of this enzyme in neuroinflammation and for assisting drug discovery. Here, we report our progress on developing a PET radioligand for RIPK1 based on the phenyl-1-dihydropyrazole skeleton of a lead RIPK1 inhibitor, GSK'963.
View Article and Find Full Text PDFSuccessful Therapy over 12 Months of People with Cystic Fibrosis with Rare Non-phe508del Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutations with Elexacaftor/Tezacaftor/Ivacaftor (ETI).
Adv Respir Med
December 2024
Department of Pediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm University, 89075 Ulm, Germany.
Elexacaftor/Tezacaftor/Ivacaftor (ETI) is a CFTR modulator therapy approved for people with cystic fibrosis (pwCF) who have at least one phe508del mutation. However, its approval in the European Union (EU) for pwCF with non-phe508del mutations is lacking, because data on treatment response in this subgroup are scarce. This retrospective observational study evaluated six pwCF (ages 6 to 66) with responsive CFTR mutations (M1101K, R347P, 2789+5G>A, G551D) undergoing off-label ETI therapy.
View Article and Find Full Text PDFEffect of glimepiride versus teneligliptin in combination with metformin in type 2 diabetes mellitus patients.
Indian J Pharmacol
September 2024
Department of Pharmacology, Melmaruvathur Adhiparasakthi Institute of Medical Sciences and Research, Chengalpattu, Tamil Nadu, India.
Background: Long-term metabolic disease type 2 diabetes mellitus (T2DM) is distinguished by elevated blood glucose, insulin resistance, and drought of insulin with dyslipidemia. Oral hypoglycemic agents lower blood glucose levels as well as prevent both short-term and long-term complications such as micro/macrovascular atherosclerosis, chronic kidney diseases, and chronic heart disease. This study aims to compare the effect of glimepiride versus teneligliptin in combination with metformin in T2DM patients attending a tertiary care hospital.
View Article and Find Full Text PDFAlopecia Areata Following the Use of Belimumab in a Patient with Systemic Lupus Erythematosus and Arthritis Who Responded Well to Baricitinib: A Case Report.
Am J Case Rep
December 2024
Department of Medicine, Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia.
Article Synopsis
- * A case study of a 54-year-old Saudi woman with SLE revealed that after conventional medication failed, treatment with belimumab improved her condition, but later led to worsening symptoms, including severe hair loss.
- * The subsequent administration of baricitinib after stopping belimumab showed significant improvement in her hair loss and arthritis symptoms, suggesting a need for focused research on specific outcomes in SLE treatment, particularly regarding baricitinib's effectiveness.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!